Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers (NCT03166072) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers
Canada150 participantsStarted 2026-04-20
Plain-language summary
Investigators aim to assess the feasibility of delivering two augmentation interventions, Meditation and a Health Enhancement Program, for potentially enhancing the quality of life and mental health of Irreversible Age-Related Vision Loss (IARVL) patients and/or their caregivers.
Who can participate
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with irreversible age-related vision loss (IARVL) and have ongoing significant disability and/or their caregivers who agree to consent.
* IARVL patients between age 60 to 85 years or caregivers between 18 to 85 years.
* Deemed competent to provide individual consent to participate.
* Speak and understand English without requirement for interpretation or assistance.
* Have no significant self-reported or physician diagnosed mental health disorder other than depressive and/or anxiety symptoms.
* Have either a minimum of CES-D 20-item scale score of 16 OR a minimum of 8 on the Hospital Anxiety Scale (HADS-A) 7-item sub-scale.
* Have sufficient hearing to be able to follow verbal instructions
* Ability to sit independently without physical discomfort for 30 minutes.
* Willing and able to attend, via Microsoft TEAMS software, the four initial training sessions of MEDITATION or HEP and at least 6 follow-up sessions.
* Willing to dedicate 33 minutes per day to their assigned home practice.
Exclusion Criteria:
* Inability to provide informed consent.
* Dementia as defined by MoCA \< 21.
* Have significant suicidal ideation as per self-report (CES-D = 3 on item question 14 and/or 15).
* Have severe depression CES-D ≥ 24.
* Participating in other similar studies.
* Have a lifetime diagnosis of self-reported other mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform d…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Participants screened
Timeframe: Through study completion, an average of 1 year
2
Participants enrolled
Timeframe: Through study completion, an average of 1 year
3
Retention rate
Timeframe: Up to 12 weeks.
4
Adherence rate
Timeframe: Up to 12 weeks
5
Assessment rating and duration
Timeframe: Up to 12 weeks
6
Intervention cost
Timeframe: Up to 12 weeks
7
Data quality
Timeframe: Up to 12 weeks
Trial details
NCT IDNCT03166072
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's